GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Gross Profit

Rapid Micro Biosystems (Rapid Micro Biosystems) Gross Profit : $-5.22 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Gross Profit?

Rapid Micro Biosystems's gross profit for the three months ended in Mar. 2024 was $-1.52 Mil. Rapid Micro Biosystems's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.22 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Rapid Micro Biosystems's gross profit for the three months ended in Mar. 2024 was $-1.52 Mil. Rapid Micro Biosystems's Revenue for the three months ended in Mar. 2024 was $5.61 Mil. Therefore, Rapid Micro Biosystems's Gross Margin % for the quarter that ended in Mar. 2024 was -27.14%.

Rapid Micro Biosystems had a gross margin of -27.14% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 5 years, the highest Gross Margin % of Rapid Micro Biosystems was -1.42%. The lowest was -50.20%. And the median was -33.32%.


Rapid Micro Biosystems Gross Profit Historical Data

The historical data trend for Rapid Micro Biosystems's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Gross Profit Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
-0.23 -8.07 -7.74 -8.54 -5.49

Rapid Micro Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.79 -1.89 -1.63 -0.17 -1.52

Competitive Comparison of Rapid Micro Biosystems's Gross Profit

For the Medical Devices subindustry, Rapid Micro Biosystems's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Micro Biosystems's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Gross Profit distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Gross Profit falls into.



Rapid Micro Biosystems Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Rapid Micro Biosystems's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=22.519 - 28.004
=-5.49

Rapid Micro Biosystems's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=5.611 - 7.134
=-1.52

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.22 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Rapid Micro Biosystems's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-1.52 / 5.611
=-27.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Rapid Micro Biosystems  (NAS:RPID) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rapid Micro Biosystems had a gross margin of -27.14% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Rapid Micro Biosystems Gross Profit Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems (Rapid Micro Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Inese Lowenstein director C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard A Keys officer: CHIEF COMMERCIAL OFFICER C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD, SUITE 280, LOWELL MA 01854